EF
NVO

Empowered Funds’s Novo Nordisk NVO Stock Holding History

Empowered Funds’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.18M Buy
66,290
+12,102
+22% +$520K 0.02% 936
2026
Q1 		$1.99M Buy
+54,188
New +$2.57M 0.01% 1108
2025
Q4 		– Sell
-51,040
Closed -$2.83M – 1609
2025
Q3 		$2.83M Sell
51,040
-23,043
-31% -$1.35M 0.03% 741
2025
Q2 		$5.11M Buy
74,083
+28,613
+63% +$1.95M 0.06% 430
2025
Q1 		$3.16M Buy
+45,470
New +$3.76M 0.04% 525

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Empowered Funds's NVO Position: Q2 2026 in Review

Empowered Funds increased its Novo Nordisk (NVO) stake by 22% in Q2 2026, buying an estimated $520K and bringing the position to 66,290 shares worth $3.18M. The position accounts for 0.02% of the portfolio, ranked #936.

Empowered Funds first reported a position in NVO in Q1 2025 and has held it in 5 quarters since. The position peaked at $5.11M in Q2 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Empowered Funds held 66,290 shares of Novo Nordisk worth $3.18M as of Q2 2026.
  • Empowered Funds bought 12,102 Novo Nordisk shares in Q2 2026, an estimated $520K.
  • Novo Nordisk made up 0.02% of Empowered Funds's portfolio in Q2 2026, its #936 holding.
  • Empowered Funds first reported a position in Novo Nordisk in Q1 2025 and has held it in 5 quarters since.
  • Empowered Funds's Novo Nordisk position peaked at $5.11M in Q2 2025.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.